Literature DB >> 9688897

Mechanisms of cardiac hypertrophy in canine volume overload.

T Matsuo1, B A Carabello, Y Nagatomo, M Koide, M Hamawaki, M R Zile, P J McDermott.   

Abstract

This study tested whether the modest hypertrophy that develops in dogs in response to mitral regurgitation is due to a relatively small change in the rate of protein synthesis or, alternatively, is due to a decreased rate of protein degradation. After 3 mo of severe experimental mitral regurgitation, the left ventricular (LV) mass-to-body weight ratio increased by 23% compared with baseline values. This increase in LV mass occurred with a small, but not statistically significant, increase in the fractional rate of myosin heavy chain (MHC) synthesis (Ks), as measured using continuous infusion with [3H]leucine in dogs at 2 wk, 4 wk, and 3 mo after creation of severe mitral regurgitation. Translational efficiency was unaffected by mitral regurgitation as measured by the distribution of MHC mRNA in polysome gradients. Furthermore, there was no detectable increase in translational capacity as measured by either total RNA content or the rate of ribosome formation. These data indicate that translational mechanisms that accelerate the rate of cardiac protein synthesis are not responsive to the stimulus of mitral regurgitation. Most of the growth after mitral regurgitation was accounted for by a decrease in the fractional rate of protein degradation, calculated by subtracting fractional rates of protein accumulation at each time point from the corresponding Ks values. We conclude that 1) volume overload produced by severe mitral regurgitation does not trigger substantial increases in the rate of protein synthesis and 2) the modest increase in LV mass results primarily from a decrease in the rate of protein degradation.

Entities:  

Keywords:  NASA Discipline Cardiopulmonary; Non-NASA Center

Mesh:

Substances:

Year:  1998        PMID: 9688897     DOI: 10.1152/ajpheart.1998.275.1.h65

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  7 in total

1.  A randomized controlled phase IIb trial of beta(1)-receptor blockade for chronic degenerative mitral regurgitation.

Authors:  Mustafa I Ahmed; Inmaculada Aban; Steven G Lloyd; Himanshu Gupta; George Howard; Seidu Inusah; Kalyani Peri; Jessica Robinson; Patty Smith; David C McGiffin; Chun G Schiros; Thomas Denney; Louis J Dell'Italia
Journal:  J Am Coll Cardiol       Date:  2012-07-18       Impact factor: 24.094

2.  New insights into the molecular phenotype of eccentric hypertrophy.

Authors:  Sebastiano Sciarretta; Junichi Sadoshima
Journal:  J Mol Cell Cardiol       Date:  2010-04-08       Impact factor: 5.000

3.  In vivo measurements of the contributions of protein synthesis and protein degradation in regulating cardiac pressure overload hypertrophy in the mouse.

Authors:  Paul J McDermott; Catalin F Baicu; Shaun R Wahl; An O Van Laer; Michael R Zile
Journal:  Mol Cell Biochem       Date:  2012-05-19       Impact factor: 3.396

Review 4.  The multiple mechanistic faces of a pure volume overload: implications for therapy.

Authors:  Justin Barnes; Louis J DellʼItalia
Journal:  Am J Med Sci       Date:  2014-10       Impact factor: 2.378

5.  Weaving hypothesis of cardiomyocyte sarcomeres: discovery of periodic broadening and narrowing of intercalated disk during volume-load change.

Authors:  Makoto Yoshida; Eiketsu Sho; Hiroshi Nanjo; Masato Takahashi; Mikio Kobayashi; Kouiti Kawamura; Makiko Honma; Masayo Komatsu; Akihiro Sugita; Misa Yamauchi; Takahiro Hosoi; Yukinobu Ito; Hirotake Masuda
Journal:  Am J Pathol       Date:  2010-01-07       Impact factor: 4.307

6.  Augmentation of autophagy by atorvastatin via Akt/mTOR pathway in spontaneously hypertensive rats.

Authors:  Wei Wang; Hao Wang; Qing-Xin Geng; Hua-Ting Wang; Wei Miao; Bo Cheng; Di Zhao; Guang-Min Song; Groban Leanne; Zhuo Zhao
Journal:  Hypertens Res       Date:  2015-07-30       Impact factor: 3.872

Review 7.  Left ventricular remodelling in chronic primary mitral regurgitation: implications for medical therapy.

Authors:  Keir McCutcheon; Pravin Manga
Journal:  Cardiovasc J Afr       Date:  2018 Jan/Feb       Impact factor: 1.167

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.